EDIT-102

N/A

Report date: 2024/09/29 16:11:11

Base Information

Drug NameEDIT-102
Drug Alias NameEDIT-102
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionGene expression modulatorsUsherin expression inhibitors
TargetsUsherin
Therapy Area/IndicationsUsher Syndromes
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEditas Medicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesEditas Medicine IncAllergan Plc
Inactive CompaniesN/A
Active IndicationsUsher Syndromes
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A